← Leaderboards
Suchismita Acharya
Ayuvis Research, Inc.
$5,432,274
Attributed
$6,417,103
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,417,103 · 5
By mechanism
R44$3,623,043 · 2
R01$1,969,658 · 1
R61$550,576 · 1
R43$273,826 · 1
Top collaborators
- Dorota Luiza Stankowska6 shared
Others in their field
Other Emerging Leaders on “Dose”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Beth Baseler · Leidos Biomedical Research, Inc.$52,807,683
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Paula Gonzalez-Maya · Fundacion Inciensa$37,578,679
- Xinhua Li · Nano Terra, Inc.$35,520,438
- Jeffrey Reich · Sparian Biosciences, Inc.$28,575,028
Research focus
DoseMouse ModelProductionCessation Of LifeCellsNovel TherapeuticsRattusAffectPreventClinical TrialsSmall MoleculePathway InteractionsAdultCell DeathSafetyAnimal ModelFutureDrug KineticsTransforming Growth Factor BetaIncidenceMacrophageIn VitroMolecular WeightOligosaccharides
Grant awards (14)
Phase 1 Safety, Pharmacokinetic study followed by Phase 2a Proof-of-Concept study of AVR-48, a small molecule macrophage modulator to prevent bronchopulmonary dysplasia in neonates$712,481
R44 · FY2025 · HD · contact PI
Phase 1 Safety, Pharmacokinetic study followed by Phase 2a Proof-of-Concept study of AVR-48, a small molecule macrophage modulator to prevent bronchopulmonary dysplasia in neonates$895,365
R44 · FY2024 · HD · contact PI
Novel hybrid molecule with both IOP lowering and neuroprotective effects for treatment of glaucoma$370,000
R01 · FY2024 · EY · contact PI
Phase-1 Healthy adult human safety and pharmacokinetic study of AVR-48, a small molecule macrophage modulator to prevent bronchopulmonary dysplasia in at-risk pre-term infants$279,788
R61 · FY2024 · HL · contact PI
A novel approach for prevention of Bronchopulmonary dysplasia in at-risk pre-term infants$702,096
R44 · FY2023 · HD · contact PI
Novel hybrid molecule with both IOP lowering and neuroprotective effects for treatment of glaucoma$370,000
R01 · FY2023 · EY · contact PI
Phase-1 Healthy adult human safety and pharmacokinetic study of AVR-48, a small molecule macrophage modulator to prevent bronchopulmonary dysplasia in at-risk pre-term infants$270,788
R61 · FY2023 · HL · contact PI
A novel approach for prevention of Bronchopulmonary dysplasia in at-risk pre-term infants$203,967
R44 · FY2023 · HD · contact PI
A novel approach for prevention of Bronchopulmonary dysplasia in at-risk pre-term infants$1,109,134
R44 · FY2022 · HD · contact PI
Novel hybrid molecule with both IOP lowering and neuroprotective effects for treatment of glaucoma$358,900
R01 · FY2022 · EY · contact PI
Novel hybrid molecule with both IOP lowering and neuroprotective effects for treatment of glaucoma$358,091
R01 · FY2021 · EY · contact PI
Sex differences in in vitro and in vivo glaucoma models may predict gender specific dose adjustment needs$147,667
R01 · FY2021 · EY · contact PI
Novel hybrid molecule with both IOP lowering and neuroprotective effects for treatment of glaucoma$365,000
R01 · FY2020 · EY · contact PI
Novel multifunctional oligosaccharide for treating sepsis and severe sepsis.$273,826
R43 · FY2017 · AI · contact PI